Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways /
[Book]
Yosef Yarden, Moshe Elkabets, editors.
Cham, Switzerland :
Springer,
2018.
1 online resource
Resistance to targeted anti-cancer therapeutics ;
volume 15
Includes bibliographical references and index.
Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
0
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Springer Nature
com.springer.onix.9783319679327
Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways.